13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595851
Total reported value
$331.0M
$331.0M
60 檔
24.9%
As reported in its official Q2 2024 Form 13F filing, Ghost Tree Capital, LLC's tracked investment portfolio stood at $331.0M with 60 total positions.
During Q2 2024, Ghost Tree Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 6.92% | — | +51.50% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 5.56% | — | +76.67% | |
| 3 | BHVN | Biohaven Ltd. | Stock-Other | 5.33% | — | +71.93% | |
| 4 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 4.13% | — | — | |
| 5 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.83% | — | +50.00% | |
| 6 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.78% | — | -28.57% | |
| 7 | ASND | Ascendis Pharma A/S | Stock-Other | 3.70% | — | — | |
| 8 | PCVX | Vaxcyte Inc | Stock-Other | 3.55% | — | +57.89% | |
| 9 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.37% | — | +20.00% | |
| 10 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.31% | — | -23.08% | |
| 11 | CATX | Perspective Therapeutics Inc | Stock-Other | 2.89% | — | — | |
| 12 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 2.79% | — | -39.39% | |
| 13 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.72% | — | -56.00% | |
| 14 | CGON | Cg Oncology Inc | Stock-Other | 2.57% | — | +246.67% | |
| 15 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.48% | — | +207.34% | |
| 16 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.39% | — | -5.97% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 2.25% | — | +133.33% | |
| 18 | IMVT | Immunovant Inc | Stock-Other | 2.15% | — | -5.45% | |
| 19 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 2.00% | — | -21.67% | |
| 20 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.94% | — | +23.71% | |
| 21 | RZLT | Rezolute Inc | Stock-Other | 1.91% | — | — | |
| 22 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.86% | — | +175.00% | |
| 23 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.84% | — | +150.24% | |
| 24 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.62% | — | +3.85% | |
| 25 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.58% | — | -37.91% | |
| 26 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.51% | — | -6.09% | |
| 27 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.35% | — | -45.03% | |
| 28 | SVRA | Savara Inc | Stock-Other | 1.33% | — | -34.32% | |
| 29 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 1.31% | — | +74.19% | |
| 30 | REPL | Replimune Group Inc | Stock-Other | 1.27% | — | -30.77% | |
| 31 | ✓ | Engene Holdings Inc | Stock-Other | 1.24% | — | +110.17% | |
| 32 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.14% | — | -47.06% | |
| 33 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.11% | — | -20.00% | |
| 34 | KRRO | Korro Bio Inc | Stock-Other | 1.06% | — | — | |
| 35 | NUVB | Nuvation Bio Inc | Stock-Other | 1.05% | — | — | |
| 36 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.96% | — | — | |
| 37 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.88% | — | +31.58% | |
| 38 | CABA | Cabaletta Bio Inc | Stock-Other | 0.87% | — | -1.09% | |
| 39 | ANNX | Annexon Inc | Stock-Other | 0.80% | — | — | |
| 40 | NGNE | Neurogene Inc | Stock-Other | 0.80% | — | +180.00% | |
| 41 | JANX | Janux Therapeutics Inc | Stock-Other | 0.66% | — | — | |
| 42 | ARVN | Arvinas Inc | Stock-Other | 0.63% | — | +87.50% | |
| 43 | RGNX | Regenxbio Inc | Stock-Other | 0.62% | — | +41.67% | |
| 44 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.56% | — | -65.05% | |
| 45 | ✓ | Elevation Oncology Inc | Stock-Other | 0.51% | — | +140.00% | |
| 46 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 0.49% | — | -39.29% | |
| 47 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.47% | — | — | |
| 48 | ATYR | Atyr Pharma Inc | Stock-Other | 0.39% | — | +33.33% | |
| 49 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.31% | — | — | |
| 50 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.29% | — | — |
According to official SEC Form 13F filings, Ghost Tree Capital, LLC reported a total U.S. public equity portfolio value of $331.0M across 60 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ALNY, INSM, BHVN) accounted for 24.9% of total reported equity market value during Q2 2024.
During Q2 2024, Ghost Tree Capital, LLC's top holdings by market value included ALNY (6.9%)、INSM (5.6%)、BHVN (5.3%). The largest single position, ALNY, represented 6.9% of total portfolio value.
In Q2 2024, Ghost Tree Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.